| Followers | 7 |
| Posts | 3129 |
| Boards Moderated | 0 |
| Alias Born | 04/21/2025 |
Monday, January 12, 2026 10:01:15 AM
CHM would advise MHRA of their findings and then MHRA would take the next step in the process. CHM advises MHRA, not the sponsor.
What Happens After Negative (or Adverse) CHM AdviceIf the CHM's final advice is negative — meaning it advises against granting the marketing authorisation — the MHRA will proceed to refuse the MAA. Key points from official MHRA guidance include:The MHRA will only refuse an application after receiving the final advice from the CHM (except in cases of technical incompleteness or failure to respond to an RFI within required timeframes).
The applicant receives a refusal letter detailing the grounds for refusal.
The decision is based on the assessment that safety, quality, or efficacy have not been adequately demonstrated, or the overall risk-benefit balance is not positive.
Appeal/Review RightsThe applicant has the right to request a review (appeal) of the refusal decision. This is set out in:Schedule 5 and paragraph 11 of Schedule 11 to the Human Medicines Regulations 2012 (as amended).
The refusal letter from the MHRA will detail the appeal process and timelines.
This may involve further representations to the CHM or other steps.
In summary, negative CHM advice is a critical step that almost invariably leads to refusal of the MAA by the MHRA, but applicants have formal appeal rights to challenge the outcome.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
